Effect of zinc supplementation on in vitro copper-induced oxidation of low-density lipoproteins in healthy French subjects aged 55-70 years: the Zenith Study.
Zn has been shown to possess antioxidant properties in vitro and in vivo. As inadequate dietary Zn intake has been reported in these populations, Zn supplementation may protect against oxidative stress and thereby limit the progression of degenerative diseases in such populations. We conducted the present study to evaluate the long-term supplementation effects of two moderate doses of Zn on in vitro Cu-induced LDL oxidation in French men and women. Three groups of sixteen healthy subjects aged 55-70 years from each sex participated in this randomized double-blind, placebo-controlled study. Each group received for six months either 0, 15 or 30 mg supplemental Zn per d. At the beginning and at the end of the supplementation periods, dietary intakes of Zn, Cu, Fe and vitamin E were estimated using 4 d food-intake records (including the weekend) and the GENI program. Zn, Cu, Fe and vitamin E status were also determined. In vitro LDL oxidizability (basal conjugated diene level, maximal conjugated diene formation and lag time) and lipid parameters were also determined. Dietary intakes of Zn, Cu, Fe and vitamin E were adequate in this population. Zn supplementation significantly increased serum Zn levels but did not significantly modify Cu, Fe or vitamin E status. However, Zn supplementation had no effect on in vitro LDL oxidation parameters, nor were there any sex-related differences in in vitro LDL oxidizability. The present study showed that long-term Zn supplementation of healthy subjects aged 55-70 years had no effect on in vitro Cu-induced LDL oxidation under the study conditions.
Feillet-Coudray
Christine
C
Centre de Recherche en Nutrition Humaine d'Auvergne, Unité Maladies Métaboliques et Micronutriments, INRA Clermont/Theix, France. cfeillet@ensam.inra.fr
Meunier
Nathalie
N
Bayle
Dominique
D
Brandolini-Bunlon
Marion
M
Andriollo-Sanchez
Maud
M
O'Connor
Jacqueline M
JM
Maiani
Giuseppe
G
Roussel
Anne-Marie
AM
Mazur
Andrzej
A
Coudray
Charles
C
D000368:Aged; D000704:Analysis of Variance; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003300:Copper / Q000008:administration & dosage* / Q000097:blood / Q000652:urine; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D017211:Treatment Failure; D014810:Vitamin E / Q000008:administration & dosage / Q000378:metabolism; D014815:Vitamins / Q000008:administration & dosage / Q000378:metabolism; D015032:Zinc / Q000008:administration & dosage* / Q000097:blood / Q000652:urine
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; D014815:Vitamins; D014810:Vitamin E; D003300:Copper; D002784:Cholesterol; D007501:Iron; D015032:Zinc